Discover the cutting-edge potential of cell-based immunotherapies in transforming the treatment landscape for glioma patients through our comprehensive umbrella review of systematic analyses.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Efficacy of cell-based immunotherapies on patients with glioma: an umbrella review of systematic reviews and meta-analysis protocol.
Nikoobakht et al., BMJ Open 2023
DOI: 10.1136/bmjopen-2023-072484
Summary of the Systematic Review on Cell-Based Immunotherapies for Glioma
Context: Glial brain tumors, particularly high-grade gliomas, have a poor prognosis despite current treatments. There is a growing interest in enhancing antitumor immunity as a novel therapeutic approach.
Objective: To systematically review the efficacy of cell-based immunotherapies for glioma, following the PRISMA guidelines.
Methods: The review will involve a comprehensive search of databases including PubMed/MEDLINE, Scopus, ISI Web of Science, EMBASE, and ProQuest for clinical trials. Data will be extracted by two independent authors after screening studies that meet inclusion criteria. Meta-analyses will be conducted, using random-effects models for heterogeneous data and fixed-effects models for homogeneous data. The risk of bias will be assessed with Begg’s and Egger’s tests, and visualized with Funnel plots.
Significance: This review aims to consolidate current knowledge on cell-based immunotherapies for glioma, which could inform future treatment strategies. It is important as it may identify effective immunotherapeutic approaches for a disease with limited treatment options.
Registration: The review protocol is registered with the identifier CRD42022373297. No ethical registration is required as the study does not involve human participants.
Publication: The findings will be disseminated through a peer-reviewed journal.
This systematic review is significant as it targets a critical area in cancer therapy, potentially guiding future research and clinical practice in the treatment of glial brain tumors.